Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Scleroderma Treatment Market: By Drug Class, By Indication, By Distribution Channels and Region Forecast 2019-2030
Scleroderma Treatment Market: By Drug Class, By Indication, By Distribution Channels and Region Forecast 2019-2030
Scleroderma Treatment Market size was valued at US$ 7.3 billion in 2023 and expected to grow at a CAGR of 7.2% from 2024 to 2030. Scleroderma is an immune system state of the connective tissue portrayed by skin thickening, unconstrained scarring, vein infection, and differing degrees of irritation, related with an overactive invulnerable framework. Immune system ailments are diseases that happen when the body's tissues are assaulted by its own safe framework. Scleroderma is described by the development of scar tissue (fibrosis) in the skin. This prompts thickness and immovability of included skin. This may likewise happen in inside organs, for example, the kidney.
The market is highly fragmented because of the many market players. These market players are progressively going up against each other in view of variables, for example, forceful evaluating and new signs. Market Players are taking endeavours to address the neglected medicinal needs by developing novel therapeutics. They are likewise concentrating on the improvement of medications in new course of organizations (ROAs, for example, topical patches). To enhance their market positions, the players in this market space additionally focusing on embracing systems, for example, M&A and distribution through partnerships. Stem cell transplants can furnish managed abatements in patients with extreme immune system infections, for example, lupus, rheumatoid joint inflammation, adolescent joint inflammation, and numerous sclerosis. The autologous platelet undeveloped cell transplants can altogether enhance the survival rate of patients experiencing scleroderma conditions
Study Period
2024-2030Base Year
2023CAGR
7.2%Largest Market
North AmericaFastest Growing Market
Asia Pacific
Expanding commonness of scleroderma and rising frequencies of hereditary transformations combined with radical changes in condition is the high effect rendering jumpers for scleroderma drugs market. As indicated by International reports from Japan and Britain, predominance of fundamental scleroderma is around 35 cases for every 1 million grown-ups. Ladies are four times more inclined to create fundamental scleroderma than men. Also, nearness of high neglected medicinal needs and the consequent acquaintance of new items providing food with these requirements are relied upon to serve scleroderma drugs market as future development opportunities.
Geographically market is segmented as Latin America, North America, Asia- Pacific, The Middle East & Africa and Europe. North America dominates the market over the forecast period. Government research development programs and favourable reimbursement scenario combined with high market infiltration rates coupled to drive scleroderma drugs market. Besides, nearness of a broad number of clinical preliminaries went for upgrading adequacy and new item improvement in the district is relied upon to fuel future market development. Asia Pacific developed as the quickest developing region attributable to an expansive nearness of neglected patient needs and the ensuing ascent in utilization rates. Moreover, nearness of good government activities in Japan and Australia is relied upon to drive the market.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 7.3 billion |
|
Market CAGR |
7.2% |
|
By Drug Class |
|
|
By Indication |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
The Scleroderma Treatment Market size was valued at US$ 7.3 billion in 2023.
The Scleroderma Treatment Market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
Asia Pacific is the fastest-growing for Scleroderma Treatment Market
| 1.Executive Summary |
| 2.Global Scleroderma Treatment Market Introduction |
| 2.1.Global Scleroderma Treatment Market - Taxonomy |
| 2.2.Global Scleroderma Treatment Market - Definitions |
| 2.2.1.Drug Class |
| 2.2.2.Indication |
| 2.2.3.Distribution Channel |
| 2.2.4.Region |
| 3.Global Scleroderma Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Scleroderma Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Scleroderma Treatment Market By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Anti- Inflammatory drugs |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Immunosuppressant |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. PDE5 inhibitors |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Calcium channel blockers |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. others |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6.Global Scleroderma Treatment Market By Indication, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Localized |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Systemic |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7.Global Scleroderma Treatment Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Retail Pharmacies |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Online Pharmacies |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Hospital Pharmacies |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Scleroderma Treatment Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Scleroderma Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Anti- Inflammatory drugs |
| 9.1.2.Immunosuppressant |
| 9.1.3.PDE5 inhibitors |
| 9.1.4.Calcium channel blockers |
| 9.1.5.others |
| 9.2. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Localized |
| 9.2.2.Systemic |
| 9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Retail Pharmacies |
| 9.3.2.Online Pharmacies |
| 9.3.3.Hospital Pharmacies |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Scleroderma Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Anti- Inflammatory drugs |
| 10.1.2.Immunosuppressant |
| 10.1.3.PDE5 inhibitors |
| 10.1.4.Calcium channel blockers |
| 10.1.5.others |
| 10.2. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Localized |
| 10.2.2.Systemic |
| 10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Retail Pharmacies |
| 10.3.2.Online Pharmacies |
| 10.3.3.Hospital Pharmacies |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 11.Asia Pacific (APAC) Scleroderma Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Anti- Inflammatory drugs |
| 11.1.2.Immunosuppressant |
| 11.1.3.PDE5 inhibitors |
| 11.1.4.Calcium channel blockers |
| 11.1.5.others |
| 11.2. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Localized |
| 11.2.2.Systemic |
| 11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Retail Pharmacies |
| 11.3.2.Online Pharmacies |
| 11.3.3.Hospital Pharmacies |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Scleroderma Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Anti- Inflammatory drugs |
| 12.1.2.Immunosuppressant |
| 12.1.3.PDE5 inhibitors |
| 12.1.4.Calcium channel blockers |
| 12.1.5.others |
| 12.2. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Localized |
| 12.2.2.Systemic |
| 12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Retail Pharmacies |
| 12.3.2.Online Pharmacies |
| 12.3.3.Hospital Pharmacies |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Scleroderma Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Anti- Inflammatory drugs |
| 13.1.2.Immunosuppressant |
| 13.1.3.PDE5 inhibitors |
| 13.1.4.Calcium channel blockers |
| 13.1.5.others |
| 13.2. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Localized |
| 13.2.2.Systemic |
| 13.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Retail Pharmacies |
| 13.3.2.Online Pharmacies |
| 13.3.3.Hospital Pharmacies |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Bristol Myers Squibb (U.S.) |
| 14.2.2.Johnson & Johnson Services, Inc. (U.S.) |
| 14.2.3.Eli Lilly and Company (U.S.) |
| 14.2.4.Pfizer, Inc. (U.S.) |
| 14.2.5.Abbott Laboratories (U.S.) |
| 14.2.6.GlaxoSmithKline plc (U.K.) |
| 14.2.7.Novartis AG (Switzerland) |
| 14.2.8.Sanofi S.A. (France) |
| 14.2.9.Astellas Pharma, Inc. (Japan) |
| 14.2.10.Bayer AG (Germany) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.